Bioanalytical Method Validation Summary — GLPI-103 (PK Assay & Anti-Drug-Antibody Assay)
| Field | Value |
|---|---|
| Document ID | BIOANALYTICAL-001 |
| Version | 1.0 |
| Status | Final |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| CTD location | Module 5.3.1.4 / 2.7.1 — Bioanalytical & analytical methods |
| Standard(s) | ICH M10 (Bioanalytical Method Validation); FDA/EMA BMV guidance |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No bioanalytical dataset is simulated. Validation parameters are illustrative and consistent with ICH M10 acceptance criteria for a peptide LC–MS/MS assay and a ligand-binding ADA assay. This document stands in for the full method-validation reports a real submission would file, and supports the PK (CLINPHARM-002) and immunogenicity (IMMUNO-001) analyses.
Change History
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-07-05 | Bioanalytical | Initial submission-grade summary of PK-assay and ADA-assay validation |
Abbreviations
ADA anti-drug antibody · CV coefficient of variation · ISR incurred-sample reanalysis · LC–MS/MS liquid chromatography–tandem mass spectrometry · LLOQ lower limit of quantification · MRD minimum required dilution · QC quality control · ULOQ upper limit of quantification.
1. Scope
Two validated methods underpin the clinical-pharmacology and immunogenicity programs: (1) a quantitative LC–MS/MS assay for GLPI-103 in human plasma (PK), and (2) a tiered ligand-binding ADA assay (screening/confirmatory/titre/neutralizing). Both were validated to ICH M10 prior to sample analysis and monitored by in-study QC and, for the PK assay, incurred-sample reanalysis.
2. PK Assay — LC–MS/MS (human plasma) [MOCK]
| Validation parameter | Result | ICH M10 acceptance |
|---|---|---|
| Analyte / internal standard | GLPI-103 / stable-isotope-labelled GLPI-103 | — |
| Calibration range (LLOQ–ULOQ) | linear over the clinical range | ≥ 75% calibrators within ±15% (±20% at LLOQ) |
| Accuracy (QC, inter-run) | within ±15% of nominal (±20% at LLOQ) | ±15% / ±20% |
| Precision (QC, inter-run CV) | ≤ 15% (≤ 20% at LLOQ) | ≤ 15% / ≤ 20% |
| Selectivity / specificity | no interference from matrix, metabolites, or co-medications (metformin, semaglutide) | met |
| Matrix effect / recovery | consistent, reproducible | met |
| Stability | bench-top, freeze–thaw, long-term frozen, autosampler — all covered | met |
| Dilution integrity | validated for above-ULOQ samples | met |
| Incurred-sample reanalysis (ISR) | ≥ 2/3 of samples within 20% | ≥ 67% within 20% |
The PK assay met all ICH M10 criteria and was fit for purpose for the pharmacokinetic analyses (CLINPHARM-002).
3. Anti-Drug-Antibody Assay — tiered ligand-binding [MOCK]
| Validation parameter | Result | Basis |
|---|---|---|
| Format | bridging electrochemiluminescence immunoassay | — |
| Screening cut point | statistically determined (target ~5% false-positive) | FDA/EMA immunogenicity guidance |
| Confirmatory cut point | competitive inhibition with excess drug (~1% false-positive) | — |
| Sensitivity | low-ng/mL surrogate positive control | fit-for-purpose |
| Drug tolerance | adequate at anticipated trough drug concentrations | — |
| Minimum required dilution (MRD) | established | — |
| Titre & neutralizing (NAb) | serial-dilution titre; competitive ligand-binding NAb | characterization tiers |
| Selectivity / matrix | no relevant interference | — |
The tiered ADA method met fit-for-purpose validation criteria and supported the integrated immunogenicity assessment (IMMUNO-001), including drug-tolerance adequate to interpret on-treatment samples and a NAb assay to characterize positive samples.
4. Conclusion
Both bioanalytical methods were validated to ICH M10 and monitored during sample analysis (in-study QC; PK ISR), establishing that the pharmacokinetic and immunogenicity conclusions rest on analytically sound data. Method details and validation are cross-referenced from Module 2.7.1 and the individual PK/immunogenicity reports.
5. References
ICH M10; FDA/EMA bioanalytical and immunogenicity guidance; CLINPHARM-002 (PK); IMMUNO-001 (immunogenicity); M2.7.1.